Possible scenario
Gradual Limited Rollout
32% Chance
The program advances, but HHS keeps it voluntary and narrow while regulators build confidence in model governance and patient-safety safeguards. Drug developers gain useful tools for trial planning, but near-term cost savings fall well short of the headline 10x target.
Secondary impacts
- Healthcare +0.6%
- Technology +0.5%
- Business Services +0.2%
Tickers
- SDGR+2.4%
- RXRX+1.5%
- TEM+1.2%
- +1.1%
Portfolio impact
S&P 500+0.3%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.